Multiple myeloma is a complex haematological malignancy that remains challenging to treat, but the introduction of targeted therapies has transformed patient outcomes. Daratumumab, a monoclonal antibody targeting CD38, has emerged as a cornerstone of multiple myeloma treatment, demonstrating significant efficacy both as monotherapy and in combination regimens. Available in intravenous and subcutaneous formulations, daratumumab offers flexibility in administration and improved convenience for patients. This therapeutic profile is driving growth in the Daratumumab Injection Market.

The Daratumumab Injection Market was valued at approximately USD 2.7 billion in 2025 and is projected to reach USD 7 billion by 2035, growing at an impressive CAGR of 10.1%. This growth is driven by the rising incidence of multiple myeloma, advancements in treatment regimens, and the expanding use of daratumumab in combination therapies. Multiple myeloma represents the largest indication segment, valued at USD 1.6 billion in 2024 and projected to reach USD 4.2 billion by 2035, reflecting the critical role of daratumumab in managing this condition.

Technological advancements are enhancing the delivery and efficacy of daratumumab. The subcutaneous formulation offers reduced administration time and improved patient convenience compared to intravenous infusion, driving its adoption in clinical practice. Additionally, ongoing research into combination therapies and new indications is expanding the therapeutic potential of daratumumab. As the oncology landscape continues to evolve, the Daratumumab Injection Market is well-positioned for sustained growth.

People Also Ask

• What is daratumumab?
  Daratumumab is a monoclonal antibody that targets CD38, used primarily to treat multiple myeloma.

• How is daratumumab administered?
  Daratumumab is administered intravenously or subcutaneously, with the subcutaneous formulation offering reduced administration time.

Tags: #Daratumumab #MultipleMyeloma #MonoclonalAntibodies #CancerTreatment #Oncology #Hematology